Skip to Content


In the US, Omalizumab (omalizumab systemic) is a member of the drug class other immunosuppressants and is used to treat Asthma - Maintenance and Urticaria.

US matches:



ATC (Anatomical Therapeutic Chemical Classification)


CAS registry number (Chemical Abstracts Service)


Chemical Formula


Molecular Weight


Therapeutic Categories

Antiasthmatic agent

Antiallergic agent


Monoclonal antibody

Chemical Name

Immunoglobulin G, anti-(human immunoglobulin E Fc region) (human-mouse monoclonal E25 clone psVIE26 gamma-chain), disulfide wit human-mouse monoclonal E25 clone psVIE26 *k63-chain, dimer (WHO)

Foreign Names

  • Omalizumabum (Latin)
  • Omalizumab (German)
  • Omalizumab (French)
  • Omalizumab (Spanish)

Generic Names

  • Omalizumab (OS: BAN, USAN)
  • Omalizumab (Genetical Recombination) (OS: JAN)
  • AL 901 (IS)
  • anti-Ig E (IS)
  • CGP 51901 (IS)
  • E25 (IS)
  • Humanized anti-IgE monoclonal antibody (IS)
  • IGE 025 (IS)
  • Monoclonal antibody E25 (IS)
  • Monoklonaler Anti-Ig E Antik├Ârper, human, rekombiniert (IS)
  • Monoklonaler Antik├Ârper E25 (IS)
  • Olizumab (IS)
  • psVIE26 *k63-chain, dimer (IS: WHO)
  • Recombinant humanized anti-IgE monoclonal antibody (IS)
  • rhu MAb-E25 (IS)
  • TNX 901 (IS)

Brand Names

  • Xolair
    Genentech, United States; Grupo Novartis, Spain; Novartis, Argentina; Novartis, Belgium; Novartis, Chile; Novartis, Colombia; Novartis, Czech Republic; Novartis, Denmark; Novartis, Ecuador; Novartis, Egypt; Novartis, Finland; Novartis, France; Novartis, Georgia; Novartis, Greece; Novartis, Hong Kong; Novartis, Croatia (Hrvatska); Novartis, Hungary; Novartis, Indonesia; Novartis, Ireland; Novartis, Israel; Novartis, Iceland; Novartis, Japan; Novartis, Lebanon; Novartis, Lithuania; Novartis, Mexico; Novartis, Malaysia; Novartis, Netherlands; Novartis, Norway; Novartis, New Zealand; Novartis, Oman; Novartis, Poland; Novartis, Portugal; Novartis, Romania; Novartis, Serbia; Novartis, Sweden; Novartis, Slovakia; Novartis, Thailand; Novartis, Turkey; Novartis, Taiwan; Novartis Biosciences, Peru; Novartis Europharm, Austria; Novartis Farma, Italy; Novartis Healthcare, Philippines; Novartis Pharma, Switzerland; Novartis Pharma, Germany; Novartis Pharma, Russian Federation; Novartis Pharmaceuticals, Australia; Novartis Pharmaceuticals, Canada; Novartis Pharmaceuticals UK, United Kingdom


BANBritish Approved Name
ISInofficial Synonym
JANJapanese Accepted Name
OSOfficial Synonym
Rec.INNRecommended International Nonproprietary Name (World Health Organization)
USANUnited States Adopted Name
WHOWorld Health Organization

Further information on drug naming conventions: International Nonproprietary Names.

Important Notice: The international database is in BETA release. This means it is still under development and may contain inaccuracies. It is not intended as a substitute for the expertise and judgement of your physician, pharmacist or other healthcare professional. It should not be construed to indicate that the use of any medication in any country is safe, appropriate or effective for you. Consult with your healthcare professional before taking any medication.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.